DJIA 18,053.71 23.50 0.13%
NASDAQ 4,806.86 33.39 0.70%
S&P 500 2,088.77 6.89 0.33%
market minute promo

PHARMACYCLICS, INC. (NASDAQ: PCYC)

124.86 3.02 (2.48%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

PCYC $124.86 2.48%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $122.38
Previous Close $121.84
Daily Range $122.35 - $125.71
52-Week Range $82.51 - $154.89
Market Cap $9.4B
P/E Ratio 108.79
Dividend (Yield) $0.00 (0.0%)
Volume 415,478
Average Daily Volume 673,763
Current FY EPS $0.90

Sector

Healthcare

Industry

Drugs

PHARMACYCLICS, INC. (PCYC) Description

A pharmaceutical company focused on the development of products that improve existing therapeutic approaches to cancer and other diseases. Website: http://www.pharmacyclics.com/

News & Commentary

Can You Guess the Best-Performing Biotech IPO of 2014? (Hint: Shares Rallied 217%)

This cancer immunotherapy treatment company's shares have soared following its IPO in June.

Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog

Pharmacyclics Reveals FDA Action Date for Imbruvica sNDA - Analyst Blog

Tuesday's ETF Movers: GDXJ, BBH

Pharmacyclics (PCYC) Is Water-Logged And Getting Wetter Today

These Biotech Stocks Are Growing Even Faster Than Gilead Sciences

Medivation Inc. and Pharmacyclics are posting even faster revenue growth than Gilead Sciences.

Bull of the Day: Seattle Genetics (SGEN) - Bull of the Day

3 Reasons Johnson & Johnson Could Soar in 2015

Following a 21% year-to-date gain, Johnson & Johnson could be poised for another strong year in 2015. Find out what three catalysts could send J&J markedly higher next year.

Pharmacyclics Presents Imbruvica Data at the ASH Meeting - Analyst Blog

Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Ma

Pharmacyclics Reports IMRUVICA Data Shows Safety, Durability of Response at Two-Year Follow-Up in Mantle Cell Lymphoma

Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog

Pharmacyclics (PCYC) Launches U.S.-Based CLL Registry - Analyst Blog

See More PCYC News...

PCYC's Top Competitors

PCYC $124.86 (2.48%)
Current stock: PCYC
CELG $113.35 (3.42%)
Current stock: CELG
AMGN $163.46 (1.74%)
Current stock: AMGN
BIIB $342.40 (0.44%)
Current stock: BIIB